<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461524</url>
  </required_header>
  <id_info>
    <org_study_id>10173339DOC</org_study_id>
    <nct_id>NCT02461524</nct_id>
  </id_info>
  <brief_title>Endurant Evo International Clinical Trial</brief_title>
  <official_title>Endurant Evo International Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety and effectiveness of the Endurant Evo AAA&#xD;
      (Abdominal Aortic Aneurysm) Stent graft system for endovascular treatment of subjects with&#xD;
      infrarenal abdominal aortic or aortoiliac aneurysms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Endurant Evo International Clinical Trial is a prospective, multi-center, premarket,&#xD;
      non-randomized, single-arm trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study terminated enrollment due to device failures prior to enrollment completion.&#xD;
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">June 25, 2021</completion_date>
  <primary_completion_date type="Actual">June 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint assessed by the proportion of subjects experiencing a MAE within 30-days post-implantation.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint assessed by the proportion of subjects with technical success at the index procedure.</measure>
    <time_frame>Index procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause-mortality</measure>
    <time_frame>within 30, 183, and 365 days, then annually until 5-Year post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm-related mortality</measure>
    <time_frame>within 30, 183, and 365 days, then annually until 5-Year post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary procedures to correct Type I and III endoleaks</measure>
    <time_frame>within 30, 183, and 365 days, then annually until 5-Year post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endovascular procedures</measure>
    <time_frame>within 30, 183, and 365 days, then annually until 5-Year post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>within 30, 183, and 365 days, then annually until 5-Year post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm rupture</measure>
    <time_frame>within 30, 183, and 365 days, then annually until 5-Year post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to open surgery</measure>
    <time_frame>within 30, 183, and 365 days, then annually until 5-Year post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse events</measure>
    <time_frame>within 183, and 365 days, then annually until 5-Year post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent graft migration (as compared to 1-month imaging)</measure>
    <time_frame>12-month, 24-month, 36-month, 48-month and 60-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm expansion &gt; 5 mm (as compared to 1-month imaging)</measure>
    <time_frame>12-month, 24-month, 36-month, 48-month and 60-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All endoleaks based on imaging findings</measure>
    <time_frame>1- month, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent graft occlusion based on imaging findings</measure>
    <time_frame>Through 6-month, 12-month, 24-month, 36-month, 48-month and 60-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device deficiencies based on imaging findings</measure>
    <time_frame>Through 6-month, 12-month, 24-month, 36-month, 48-month and 60-month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <condition>AAA</condition>
  <arm_group>
    <arm_group_label>Endovasculair repair</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Endurant Evo AAA Stent graft system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endurant Evo AAA Stent Graft System</intervention_name>
    <arm_group_label>Endovasculair repair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular aneurysm repair (EVAR)</intervention_name>
    <arm_group_label>Endovasculair repair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥ 18 years old&#xD;
&#xD;
          2. Subject understands and voluntarily has signed and dated the Informed Consent approved&#xD;
             by the Sponsor and by the Ethics Committee/Institutional Review Board.&#xD;
&#xD;
          3. Subject is able and willing to comply with the protocol and to adhere to the follow-up&#xD;
             requirements&#xD;
&#xD;
          4. Subject is a suitable candidate for elective surgical repair of AAA as evaluated by&#xD;
             American Society of Anesthesiologists (ASA) Physical Status Classification System I,&#xD;
             II, or III&#xD;
&#xD;
          5. Subject has an infrarenal abdominal aortic or aortoiliac aneurysm characterized by one&#xD;
             or more of the following:&#xD;
&#xD;
               -  Aneurysm is &gt; 5 cm in diameter (diameter measured is perpendicular to the line of&#xD;
                  flow)&#xD;
&#xD;
               -  Aneurysm is 4 - 5 cm in diameter and has increased in size ≥ 0.5 cm within the&#xD;
                  previous 6 months&#xD;
&#xD;
          6. Subject meets all the following anatomical criteria as demonstrated on&#xD;
             contrast-enhanced CT or MRA (Magnetic Resonance Angiography) imaging:&#xD;
&#xD;
               -  Proximal neck length of ≥ 10 mm with ≤ 60° infrarenal and ≤ 45° suprarenal neck&#xD;
                  angulation or Proximal neck length of ≥ 15 mm with ≤ 75° infrarenal and ≤ 60°&#xD;
                  suprarenal neck angulation&#xD;
&#xD;
               -  Subject has vascular dimensions, e.g., aortic and iliac diameters, lengths from&#xD;
                  renal arteries to iliac bifurcation and hypogastric arteries, in the range of&#xD;
                  sizes available for the Endurant Evo AAA stent graft system (measured intima to&#xD;
                  intima) and within the sizing recommendations (refer to Endurant Evo AAA stent&#xD;
                  graft system Instructions for Use (IFU))&#xD;
&#xD;
               -  Subject has a proximal aortic neck diameter ≥18 mm and ≤32 mm&#xD;
&#xD;
               -  The distal fixation center of the iliac arteries must have a diameter ≥7 mm and ≤&#xD;
                  25 mm bilaterally for the bifur and unilaterally for the Aorto-Uni-Iliac (AUI)&#xD;
&#xD;
               -  Subject has documented imaging evidence of at least one patent iliac and one&#xD;
                  femoral artery, or can tolerate a vascular conduit that allows introduction of&#xD;
                  the Endurant Evo AAA stent graft system&#xD;
&#xD;
               -  Subject has distal non-aneurysmal iliac (cylindrical) fixation length ≥ 20 mm&#xD;
                  bilaterally for the bifur and unilaterally for the AUI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a life expectancy ≤ 1 year&#xD;
&#xD;
          2. Subject is participating in another investigational drug or device study which would&#xD;
             interfere with the endpoints and follow-ups of this study&#xD;
&#xD;
          3. Subject is pregnant&#xD;
&#xD;
          4. Subject has an aneurysm that is:&#xD;
&#xD;
               -  Suprarenal/ pararenal/ juxtarenal&#xD;
&#xD;
               -  Isolated ilio-femoral&#xD;
&#xD;
               -  Mycotic&#xD;
&#xD;
               -  Inflammatory&#xD;
&#xD;
               -  Pseudoaneurysm&#xD;
&#xD;
               -  Dissecting&#xD;
&#xD;
               -  Ruptured&#xD;
&#xD;
               -  Leaking but not ruptured&#xD;
&#xD;
          5. Subject requires emergent aneurysm treatment&#xD;
&#xD;
          6. Subject has a known, untreated thoracic aneurysm &gt;4.5 cm in diameter at time of&#xD;
             screening&#xD;
&#xD;
          7. Subject has been previously treated for an abdominal aortic aneurysm&#xD;
&#xD;
          8. Subject has a history of bleeding diathesis or coagulopathy&#xD;
&#xD;
          9. Subject has had or plans to have an unrelated major surgical or interventional&#xD;
             procedure within 1 month before or after implantation of the Endurant Evo AAA stent&#xD;
             graft&#xD;
&#xD;
         10. Subject has had a myocardial infarction (MI) or cerebral vascular accident (CVA)&#xD;
             within 3 months prior to implantation of the Endurant Evo AAA stent graft&#xD;
&#xD;
         11. Subject has a conical neck defined as a &gt;4 mm distal increase from the lowest renal&#xD;
             artery over a 10 mm length&#xD;
&#xD;
         12. Subject has a known allergy or intolerance to the device materials&#xD;
&#xD;
         13. Subject has a known hypersensitivity or contraindication to anticoagulants,&#xD;
             antiplatelets, or contrast media, which is not amenable to pre-treatment&#xD;
&#xD;
         14. Subject has significant aortic thrombus and/or calcification at either the proximal or&#xD;
             distal attachment centers that would compromise fixation and seal of the device at the&#xD;
             discretion of the investigator&#xD;
&#xD;
         15. Subject has ectatic iliac arteries requiring bilateral exclusion of hypogastric blood&#xD;
             flow&#xD;
&#xD;
         16. Subject whose arterial access site is not anticipated to accommodate the diameter of&#xD;
             the Endurant Evo AAA delivery system (13F-17F) due to vessel size, calcification, or&#xD;
             tortuosity&#xD;
&#xD;
         17. Subject is morbidly obese or has other documented clinical conditions that severely&#xD;
             inhibit radiographic visualization of the aorta at the discretion of the investigator&#xD;
&#xD;
         18. Subject has active infection at the time of the index procedure documented by e.g.&#xD;
             pain, fever, drainage, positive culture and/or leukocytosis considered to be&#xD;
             clinically significant per investigator discretion&#xD;
&#xD;
         19. Subject has congenital degenerative collagen disease, e.g., Marfan's Syndrome&#xD;
&#xD;
         20. Subject has a creatinine level &gt;2.00 mg/dl (or &gt;176.8 µmol/L)&#xD;
&#xD;
         21. Subject is on dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hence Verhagen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Hietzing</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate - Locatie Arnhem</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus Malmö</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

